| Characteristic |
Number of patients (%) (n = 12) |
| Appropriate |
10 (83.3%) |
| Targeted therapy supported by cultures |
6 |
| Septic shock or severe infection with a history of infection in the past 6 months with a B-lactam-resistant organism |
0 |
| Septic shock or severe infection with a history of multiple antibiotics given or colonization with a B-lactam-resistant organism |
0 |
| Severe neutropenia with a history of multiple antibiotics given or colonization with a B-lactam-resistant organism |
0 |
| Concern for necrotizing pancreatitis |
0 |
| Persistent fever or hemodynamic instability in patients already receiving broad-spectrum B-lactam |
2 |
| Severe infection in a patient who has received broad-spectrum B-lactam therapy for a 5-day course in the past 30 days |
0 |
| As recommended or approved by infectious disease consult |
2 |
| Suboptimal |
2 (16.7%) |
| Severe sepsis of unknown cause |
0 |
| Healthcare-associated pneumonia |
1 |
| Severe intra-abdominal infection |
1 |
| Severe neutropenia |
0 |
| Community-acquired pneumonia with bronchiectasis or cystic fibrosis |
0 |
| Limb- or life-threatening diabetic foot or soft tissue infection |
0 |
| Urinary tract infection |
0 |
| Inappropriate |
0 (0%) |
| Penicillin allergy |
0 |
| Treatment of a colonizing organism |
0 |
| Treatment resulting from presumed contaminated culture |
0 |
| Any indication not mentioned above |
0 |
